Oragenics Inc. (OGEN)
OGEN moved a median of -0.79% 30 minutes after news, and -1.10% by the close. How OGEN actually reacts to news — the realized, point-in-time move the market made, measured across 245 labeled events over the last three years with zero look-ahead.
OGEN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.01% | 29% | 225 |
| 30-min | -0.79% | 33% | 243 |
| 60-min | -0.95% | 34% | 244 |
| to close | -1.10% | 35% | 245 |
| Middle 50% of OGEN reactions | -2.70% to +1.35% |
|---|---|
| Median reaction (30-min) | -0.79% |
| Measured reactions | 245 |
Half of all Oragenics Inc. news events land between -2.70% and +1.35% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when OGEN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to OGEN's baseline. Nothing else.
Recent OGEN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K ORAGENICS INC For: Sep 16 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.00% | |
| Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation Forum | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Form 8-K ORAGENICS INC For: Aug 26 | SEC filing · Form 8-K | SEC EDGAR | -1.92% | -1.01% | |
| Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update | Press release | GlobeNewswire | -1.92% | -1.01% | |
| Form 10-Q ORAGENICS INC For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -1.13% | |
| Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling | Press release | GlobeNewswire | — | -3.18% | |
| Form 8-K ORAGENICS INC For: Jun 29 | SEC filing · Form 8-K | SEC EDGAR | — | -3.18% | |
| Form DEF 14A ORAGENICS INC For: May 20 | SEC filing · Form DEF | SEC EDGAR | — | +0.12% | |
| Form DEFA14A ORAGENICS INC | SEC filing · Form DEFA14A | SEC EDGAR | — | +0.12% | |
| Form 8-K ORAGENICS INC For: May 18 | SEC filing · Form 8-K | SEC EDGAR | -0.99% | -2.08% | |
| Oragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21 | Press release | GlobeNewswire | -0.99% | -2.08% | |
| ORAGENICS PROVIDES INVESTOR UPDATE | Press release | GlobeNewswire | +1.70% | -3.20% | |
| Form 10-Q ORAGENICS INC For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -5.27% | |
| Form PRE 14A ORAGENICS INC For: May 08 | SEC filing · Form PRE | SEC EDGAR | +0.00% | -5.27% | |
| Form 8-K ORAGENICS INC For: May 07 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -3.24% | |
| Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation | Press release | GlobeNewswire | +0.00% | -3.24% | |
| Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury. | Press release | GlobeNewswire | +0.00% | +2.67% | |
| Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury | Press release | GlobeNewswire | -4.42% | -8.18% | |
| Form 8-K ORAGENICS INC For: Apr 13 | SEC filing · Form 8-K | SEC EDGAR | +0.17% | +19.47% | |
| Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury | Press release | GlobeNewswire | +0.17% | +19.47% | |
| Form 8-K ORAGENICS INC For: Mar 27 | SEC filing · Form 8-K | SEC EDGAR | — | -3.71% | |
| Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation | Press release | GlobeNewswire | -1.26% | -8.66% | |
| Form EFFECT ORAGENICS INC | SEC filing · Form EFFECT | SEC EDGAR | -4.02% | -8.80% | |
| Form S-3/A ORAGENICS INC | SEC filing · Form S-3 | SEC EDGAR | -0.14% | +0.68% | |
| ORAGENICS FILES ANNUAL REPORT ON FORM 10-K | Press release | GlobeNewswire | +4.13% | +1.81% | |
| Form 10-K ORAGENICS INC For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +4.13% | +1.81% | |
| ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION | Press release | GlobeNewswire | -1.92% | -2.97% | |
| Form 8-K ORAGENICS INC For: Mar 10 | SEC filing · Form 8-K | SEC EDGAR | -1.92% | -2.97% | |
| ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION | Press release | GlobeNewswire | -1.92% | -14.96% | |
| Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia | Press release | GlobeNewswire | -4.15% | -0.85% | |
| Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy | Press release | GlobeNewswire | -5.01% | -8.55% | |
| Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program | Press release | GlobeNewswire | +3.15% | -0.31% | |
| Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care | Press release | GlobeNewswire | -4.84% | -0.31% | |
| Form 8-K ORAGENICS INC For: Jan 22 | SEC filing · Form 8-K | SEC EDGAR | -1.16% | -0.22% | |
| Form S-3 ORAGENICS INC | SEC filing · Form S-3 | SEC EDGAR | -1.16% | -0.22% | |
| Form 8-K ORAGENICS INC For: Jan 20 | SEC filing · Form 8-K | SEC EDGAR | -2.63% | +2.10% | |
| Oragenics to Present at the 2026 Sequire Investor Summit in Puerto Rico | Press release | GlobeNewswire | -2.64% | +0.65% | |
| Form 8-K ORAGENICS INC For: Dec 11 | SEC filing · Form 8-K | SEC EDGAR | — | -0.58% | |
| Form 8-K ORAGENICS INC For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | +1.72% | +0.00% | |
| Oragenics Q3 2025 Shareholder Update | Press release | Business Wire | +1.72% | +0.00% | |
| Form 10-Q ORAGENICS INC For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +3.70% | |
| Form 8-K ORAGENICS INC For: Oct 16 | SEC filing · Form 8-K | SEC EDGAR | -3.91% | -5.52% | |
| Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency | Press release | Business Wire | -3.91% | -5.52% | |
| Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development | Press release | Business Wire | -1.53% | +4.58% | |
| Form 8-K ORAGENICS INC For: Sep 01 | SEC filing · Form 8-K | SEC EDGAR | -0.94% | +0.94% | |
| Form S-8 ORAGENICS INC | SEC filing · Form S-8 | SEC EDGAR | +0.00% | +0.00% | |
| Form 8-K ORAGENICS INC For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | +0.86% | +0.86% | |
| Oragenics Q2 2025 Shareholder Update | Press release | GlobeNewswire | +0.86% | +0.86% | |
| Form 10-Q ORAGENICS INC For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.86% | +0.86% | |
| Oragenics Selects Southern Star Research as Clinical Research Organization for ONP-002 Phase IIa Trial | Press release | GlobeNewswire | +0.02% | -2.33% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the OGEN section they belong to.
Where else OGEN is measured.
OGEN earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Cumberland Pharmaceuticals Inc. (CPIX) | 245 | 0.00% | 49% |
| electroCore, Inc. (ECOR) | 245 | 0.00% | 47% |
| Universal Health Services, Inc. (UHS) | 245 | -0.04% | 49% |
| UNUM THERAPEUTICS INC COMMON (UMRX) | 245 | -0.89% | 41% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Oragenics Inc.'s median reaction calculated?
Every labeled OGEN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 245 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 33% of OGEN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does OGEN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.